BetterLife Provides Shareholder Update and 2021 Product Development Roadmap
(firmenpresse) - VANCOUVER, January 12, 2021 -- BetterLife Pharma Inc. (BetterLife or the Company) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to provide an overview of the Companys primary plans for this calendar year to develop 3 novel therapeutic products each addressing significant unmet needs with multi-billion dollar market potential.
The last 6 months of 2020 have been a very transformational time period for BetterLife Pharma, filled with milestones, an appreciating stock price and the development of a future roadmap to increased growth and shareholder value. Not only are we aggressively developing cutting edge next generation psychedelic products such as TD-0148A to become a leader in an emerging market with a projected 6.85 Billion dollar value by 2027 alone. But we are also seeing great progress in our development of AP-003 for the treatment of pandemic respiratory viral infections and AP-001 cream formulation for the treatment of human papilloma virus. We are also very much looking forward to our meeting with the FDA in early March. Today I am very proud and excited to share this roadmap for 2021 and beyond with the past, present and future shareholders of our emerging company. Said Ahmad Doroudian, CEO of BetterLife Pharma Inc.
TD-0148A
TD-0148A (2-bromo-lysergic acid diethylamide; 2-bromo-LSD) is an orally administered non-hallucinogenic analog of LSD. BetterLife plans to develop TD-0148A in the treatment of mental disorders such as severe depression, post-traumatic stress disorder and substance dependencies. The Companys initial clinical focus will be in treatment resistant depression.
BetterLife is planning to have a pre-IND meeting with the US FDA in Q2, with the goal to file an IND and initiate a Phase 1 clinical trial in healthy volunteers in this calendar year.
Subject to health regulatory authorities approval, the Company is also planning independent investigator studies in parallel with the IND filing to begin in Q1-Q2.
TD-0148As patented process allows for cost effective manufacturing of TD-0148A, does not use LSD as starting point nor generates LSD at any stage in the process. The Company will conduct process development, scale-up and GMP manufacturing of TD-0148A during this calendar year, leading up to the IND. The Company will also conduct the necessary IND-enabling preclinical studies in the same time frame.
AP-003
AP-003 is a BetterLife patent protected interferon alpha 2b (IFN-a2b) inhalation formulation. The Company is developing AP-003 for the treatment of pandemic respiratory viral infections, with the initial focus being early stage COVID-19. AP-003 can be self-administered by the patient at home via a nebulizer. Based on guidance received from the US FDA, the Company has initiated the necessary preclinical IND-enabling studies, with the goal to file the IND by Q3 of this calendar year.
Subject to health regulatory authorities approval, the Company is also considering conduct of AP-003 trials in COVID-19 patients in Q1-Q2 in ex-North American territories, using previously manufactured AP-003.
The Company is quite advanced in its process development and scale-up of its proprietary IFN-a2b manufacturing, which it aims to complete by end Q1 of this calendar year. If these studies are executed, a bridging clinical trial between the old and new manufactured AP-003 will also be conducted to enable use of the ex-North American data as supportive for the US IND. The Company hopes to be able to initiate a registration directed study in the US following the IND.
AP-001
AP-001 is a BetterLife patent protected IFN-a2b cream formulation. The Company is developing AP-001 for the treatment of human papilloma virus induced high-grade cervical intra-epithelial neoplasia, the precursor to cervical cancer. Current treatments for this indication are all invasive with risk of side effects, requiring professional health care intervention.
AP-001 is being developed as a patient self-administered (once-daily) intra-vaginal cream as a 6 week treatment. By Q3 of this calendar year, the Company plans to have completed process development and scale-up of the AP-001 cream and initiate the GMP manufacturing. The Company plans to have a pre-IND meeting with the FDA Q3 of this calendar year, and initiate the IND-enabling studies shortly thereafter, with the goal to file an IND by Q1 of next calendar year.
About BetterLife Pharma Inc.
BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next generation psychedelic products for the treatment of mental disorders. Utilizing drug delivery platform technologies BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus.
For further information please visit www.abetterlifepharma.com.
Contact Information:
Ahmad Doroudian, Chief Executive Officer
Email: Ahmad.Doroudian(at)blifepharma.com
Phone: 604-221-0595
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as will, may, should, anticipate, expects and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Companys expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Noram Resumes Drill Program: Positive Outlook with Neighbouring Albemarle Expansion and Focus on Clays Datum: 12.01.2021 - 02:07 Uhr
Sprache: Deutsch
News-ID 1563655
Anzahl Zeichen: 4653
contact information:
Contact person:
Town:
Wien
Phone:
Kategorie:
Business News
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 189 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BetterLife Provides Shareholder Update and 2021 Product Development Roadmap
"
steht unter der journalistisch-redaktionellen Verantwortung von
BetterLife Pharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
